Policy / Pricing SCOTUS won’t hear pharma’s IRA complaints PharmaphorumThe US Supreme Court has refused to consider lawsuits from pharma groups challenging Medicare's drug pricing negotiation powers.Read full story pharminent May 19, 2026 (Last updated: May 19, 2026) Pharmaphorum The US Supreme Court has refused to consider lawsuits from pharma groups challenging Medicare’s drug pricing negotiation powers. Read full story Post navigation Previous: 225: An Interview With Craig Martin, Founder and CEO of the Orphan Therapeutics AcceleratorNext: Regeneron signs $2.32bn deal with Parabilis for Helicon conjugates Related Stories Policy / Pricing MFN affecting Swiss medicines access, says Interpharma pharminent August 13, 2026 Policy / Pricing Prior Authorization Metrics Provide New Insights into Insurer Practices, but Gaps Remain pharminent August 13, 2026 Policy / Pricing Trump signs order that nearly halves childhood immunisation coverage pharminent August 11, 2026
